# A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

> **NCT04015024** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** SKLB1028 150mg bid
- **DRUG:** SKLB1028 200mg bid
- **DRUG:** SKLB1028 300mg qd

## Key facts

- **NCT ID:** NCT04015024
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07
- **Primary completion:** 2021-04
- **Final completion:** 2021-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04015024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04015024, "A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04015024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*